Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised double-blind placebo-controlled trial of inhaled SNG001 (interferon beta-1a) in COVID-19
2020-001023-14Phase 2Unknown
- Sponsor
- Synairgen
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing SNG001 (interferon beta-1a) inhalation with Placebo inhalation (2 arms). Primary endpoints: Safety and tolerability of SNG001 and Recovery of lower respiratory tract illness. Status: unknown.
02
Drugs
interferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001023-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001023-14.